体重与直接口服抗凝药III期随机对照试验疗效及安全性结局的关联:系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE和EMBASE至2016年11月,纳入11项直接口服抗凝药(DOAC)III期随机对照试验。低体重与血栓栓塞风险升高相关(RR 1.57;95%CI 1.34-1.85),高体重与非高体重相比血栓栓塞风险无显著关联(RR 0.88;95%CI 0.63-1.23)。所有体重比较中出血结局相当,未发现抗凝药类型与结局间存在明确交互作用。
要点
- 低体重者血栓栓塞风险较高(RR 1.57;95%CI 1.34-1.85),高体重与非高体重无显著差异(RR 0.88;95%CI 0.63-1.23)。
- 所有体重比较中出血结局相当。
- 抗凝药类型与各结局间未发现明确交互作用。
核心结论
- DOAC组与对照组的合并效应可能归因于各体重类别基线血栓风险差异,而非所用DOAC类型或剂量效应。
- 超出说明书推荐范围的DOAC剂量调整不太可能改善安全性或疗效。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE和EMBASE至2016年11月。
- 纳入房颤(AF)和急性静脉血栓栓塞症(VTE)的DOAC III期随机对照试验,共11项。
- 计算相对风险(RR)及95%置信区间(CI),采用Mantel-Haenszel随机效应模型进行合并估计。
主要发现
- 低体重与非低体重相比,血栓栓塞风险升高(RR 1.57;95%CI 1.34-1.85)。
- 高体重与非高体重相比,血栓栓塞风险无显著关联(RR 0.88;95%CI 0.63-1.23)。
- 房颤高体重亚组与非高体重相比,血栓栓塞风险降低(RR 0.43;95%CI 0.28-0.67)。
- 所有体重比较中出血结局相当。
- 所有结局中抗凝药类型间未发现明确交互作用。
临床怎么用
- 超出说明书推荐范围的DOAC剂量调整不太可能改善安全性或疗效(作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials The association of body weight and patient-important outcomes remains unknown. Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were searched. Risk of outcomes varying among body weight subgroups is not attributable to anticoagulant type. Dose adjustment of DOACs, outside that recommended, is unlikely to improve the outcomes. Click to hear Dr Braunwald's perspective on antithrombotic therapy in cardiovascular disease SUMMARY: Background Concerns have arisen in direct oral anticoagulant (DOAC)-treated patients about safety and efficacy in extremes of body weight. The aims of this systematic review were to investigate the association of body weight and patient-important outcomes in patients treated with DOACs or warfarin, and to demonstrate the fixed-dose effect of DOACs. Methods MEDLINE and EMBASE were searched until November 2016. Phase III randomized controlled trials (RCTs) using DOACs in atrial fibrillation (AF) and acute venous thromboembolism (VTE) were included. Relative risk and 95% confidence interval were calculated. The pooled estimates were performed using a Mantel-Haenszel random effects model. Results A total of 11 phase III RCTs were included. Low body weight was associated with increased risk of thromboembolism compared with non-low body weight (relative risk [RR], 1.57; 95% confidence interval [CI], 1.34-1.85). High body weight was not associated with risk of thromboembolism compared with non-high body weight (RR, 0.88; 95% CI, 0.63-1.23). The subgroup of AF patients with high body weight had a lower risk of thromboembolism compared with non-high body weight (RR, 0.43; 95% CI, 0.28-0.67). Bleeding outcomes were comparable for all body weight comparisons. There were no clear interactions between types of anticoagulant in all outcomes. Conclusion The pooled effect of both the DOAC and comparison arms was likely to be attributable to differences in baseline thrombotic risk in each body weight category, rather than an effect of the type or dose of DOAC used for each indication. Dose adjustment of DOACs, outside that recommended in the package insert, is unlikely to improve safety or efficacy.
引用
- Boonyawat K, Caron F, Li A, et al. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017. PMID: 28407368. doi:10.1111/jth.13701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。